Advances of Targeted Therapy in Cervical Cancer

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue focused on the advances of targeted therapy in cervical cancer (CC). CC still represents the fourth most common cancer among the female population, and the fourth cause of cancer-related deaths worldwide. It is typically present among younger patients, with a median age of 49 years at diagnosis. In the metastatic stage, the 5-year survival rate is only 17.6%. Platinum-based chemotherapy represents a milestone for the treatment of CC; however, therapeutic options after progression and survival are limited. Therefore, the search for new therapeutic approaches is still an unmet need for CC.

The Cancer Genome Atlas (TCGA) project focused on identifying altered pathways that may lead to tumorigenesis, as well as be used as prognostic or therapeutic markers. TCGA work led to the identification of genetic aberrations and pathways that can be exploited therapeutically as new potential targeted therapy markers. This Special Issue aims to collect papers of targeted therapies in CC. Though all studies regarding targeted therapy for CC will be considered for publishing, priority will be given to original research regarding advances and innovations of targeted therapies for CC, giving future perspectives and outlining how these advances will reshape the future CC therapeutic scenario. Areas of special interests could be, but are not limited to, the newest targeted therapy pathways, such as VEGF/VEGFR and CD274 (PD-L1), and more generally the use of ICIs, EGFR, mTOR, PARP and the role of PARPis, vaccines and antibody–drug conjugates.

We look forward to receiving your contributions.

Dr. Vera Loizzi
Dr. Gennaro Cormio
Dr. Brigida Anna Maiorano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cervical cancer
• targeted therapy
• HPV
• ICI
• immunotherapy
• VEGF
• vaccine
• PARP